Research published in eBioMedicine confirmed that cagrilintide lowers body weight specifically through brain amylin receptors 1 and 3 (AMY1R and AMY3R), and these are distinct from the receptors that GLP-1 agonists activate
This week, the FDA's Pharmacy Compounding Advisory Committee is expected to recommend whether seven peptides can move to the Section 503A Bulk Drug Substances List, a recommendation that could have significant implications for patient access, personalized care, and the future of compounding
Vaccination has been very successful at reducing the prevalence of this disease
Fullerton JN, Segre E, De Maeyer RP, et al
This pro-osteogenic effect operates through the cAMP/CREB signaling pathway
*Correspondence: Tiansong Yang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
